8-K: Earth Science Tech Reports Strong Q2 Fiscal 2025

Earth Science Tech, Inc. announced significant financial and operational growth for its second fiscal quarter ended September 30, 2025, including a 71.64% increase in total assets.

Summary

• Total Assets increased by 71.64% year-over-year, reaching $8.66 million, up from $5.04 million in Q2 2024.
• Total Assets grew 22.65% year-to-date from $7.07 million at the March 31, 2025, year-end.
• Outstanding common shares were reduced by 3.57% year-over-year to 292.8 million shares.
• Quarterly Net Profit increased by 18.48% to $0.94 million.
• Quarterly Revenue grew by 6.24% to $9.05 million.
• Gross Profit increased by 7.3% to $6.72 million.
• The company operates as a strategic holding company focused on acquiring, optimizing, and managing high-potential operating businesses in compounding pharmaceuticals, telemedicine, and real estate development.

Sentiment

Score: 9

Explanation: The company reported significant year-over-year and year-to-date growth in total assets, substantial increases in net profit, revenue, and gross profit, alongside a reduction in outstanding shares, indicating strong operational execution and a commitment to shareholder value.

Positives

• Total Assets increased significantly by 71.64% year-over-year to $8.66 million.
• Total Assets grew 22.65% year-to-date from $7.07 million.
• Outstanding common shares were reduced by 3.57% year-over-year, enhancing shareholder value.
• Quarterly Net Profit rose by 18.48% to $0.94 million.
• Quarterly Revenue increased by 6.24% to $9.05 million.
• Gross Profit increased by 7.3% to $6.72 million.
• The company is actively expanding its licensure for compounding pharmacies (RxCompoundStore.com and Mister Meds) across the U.S.
• Expansion into new markets, including veterinary telemedicine through Zoolzy.com and premium BBQ tools through BBQraft, demonstrates strategic growth.

Risks

• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.
• Risks include those related to the markets for products and services.
• Costs of goods and services, and other expenses, pose potential risks.
• Government regulations could impact operations and financial performance.
• Litigations are a potential risk factor.
• General business conditions could affect the company's results.

Future Outlook

The company's subsidiaries are actively pursuing licensure in additional U.S. states for compounding pharmacies (RxCompoundStore.com and Mister Meds) and aiming to offer telemedicine services nationwide through Peaks Curative. MagneChef is in the process of expanding its product line for new offerings incorporating its intellectual property.

Management Comments

• "Our second quarter demonstrates successful execution of our strategy to scale high-potential businesses."
• "The 71% year-over-year growth in total assets, coupled with a 22.65% asset increase since our March year-end, and our continued efforts to reduce the outstanding common share count by over 3.5% are direct measures of our focus on driving fundamental growth and increasing value for our shareholders."

Industry Context

The company operates as a strategic holding company, actively acquiring and scaling businesses across diverse sectors including compounding pharmaceuticals, telemedicine, real estate development, and direct-to-consumer retail. This strategy aligns with broader industry trends of consolidation, diversification, and leveraging specialized healthcare services and e-commerce. The expansion into veterinary telemedicine and premium consumer goods demonstrates a broad and opportunistic approach to market growth.

Stakeholder Impact

• Shareholders: Benefit from increased asset value, higher profitability, and a reduction in outstanding common shares, indicating enhanced shareholder value.
• Customers: Gain expanded access to compounding pharmacy and telemedicine services as subsidiaries pursue broader state licensure and develop new platforms.
• Employees: Potential for growth and expansion within the company's diverse portfolio of operating businesses.
• Community: Earth Science Foundation, Inc. provides financial support for prescription costs at the company's pharmacies, serving a charitable role.

Next Steps

• RxCompoundStore.com is actively pursuing licensure in the remaining U.S. states.
• Mister Meds is applying for licensure in states not yet serviced by RxCompound.
• Peaks Curative is developing its own healthcare provider network (MyOnlineConsultation.com) and expanding pharmacy licensure to offer services nationwide.
• MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property.

Key Dates

Recommendation

The company's Q2 Fiscal 2025 results demonstrate robust financial health and strategic execution, with significant year-over-year asset growth, increased profitability, and a commitment to shareholder value through share count reduction. The diversified portfolio of operating businesses in growing sectors like compounding pharmaceuticals, telemedicine, and real estate, coupled with ongoing expansion efforts, positions the company for continued growth. These strong fundamentals and clear strategic direction make it a compelling investment.

Keywords

Earth Science Tech, ETST, Q2 2025 results, financial performance, asset growth, net profit, revenue growth, shareholder value, holding company, compounding pharmacy, telemedicine, real estate development, share repurchase program